Oct

    Servier: Europe's Second Outing on "Pay-for-Delay"- Are the Mists Clearing?

    12 PM EDT

    Pay-for-delay just got more complex. In Servier, the Court nixes the EU's market definition – declining to find a molecule wide market – and nuances an absolutest stance on per se illegality. It sets a high bar for justifying reverse payments. Pure cash and "sweetheart" distribution deals are out. But authorized generics and paid IP transfers can be benign. While far from the US' rich seam of cases, Europe's second outing provides surprises, and some clarity, for enforcers and practitioners.

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Join now to receive additional discounts
    Join and Buy – NOW

    Our panel will debate these issues: Blaz Visnar, European Commission, Jeremy Jourdan, White & Case, counsel to Servier, and Keo Shaw, Baker McKenzie, counsel to Unichem

    Moderator:
    Bill Batchelor, Skadden

    Speakers:
    Jeremy Jourdan, White & Case
    Keo Shaw, Baker McKenzie
    Blaz Visnar, European Commission

    Antitrust Section Members, Government, Non-Profit Employees, Students, $25 Other Non-Members.

    Explore Section benefits or call 1-800-285-2221 to join. To learn more: https://www.americanbar.org/groups/antitrust_law/

    The ABA is not seeking CLE credit for this program.

    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

    Event Details

    Format

    Teleconference

    Date

    Oct 01, 2019

    2019-10-01T12:00:00-04:00 2019-10-01T13:00:00-04:00 Servier: Europe's Second Outing on "Pay-for-Delay"- Are the Mists Clearing?

    Pay-for-delay just got more complex. In Servier, the Court nixes the EU's market definition – declining to find a molecule wide market – and nuances an absolutest stance on per se illegality. It sets a high bar for justifying reverse payments. Pure cash and "sweetheart" distribution deals are out. But authorized generics and paid IP transfers can be benign. While far from the US' rich seam of cases, Europe's second outing provides surprises, and some clarity, for enforcers and practitioners.

    Sponsors

    Health Care and Pharmaceuticals Committee

    Section of Antitrust Law

    Moderators

    Related Products

    Related On-Demand CLE